autoimmune Disease
The future of autoimmune drugs in hives
Dupixent, a blockbuster from Sanofi and Regeneron, treated patients with chronic spontaneous urticaria in a Phase 3 trial — showing a significant decrease in itch severity and hives compared to placebo.
The study, Liberty-Cupid Study C, found that 30% of Dupixent-treated patients were hive- and itch-free after six months, versus 18% on placebo, with similar safety profiles between the groups. These results come after the FDA rejected Dupixent's application last year, requesting additional data following a failed trial.
Read more.
diabetes
Lilly releases new data on weekly insulin
From STAT's Elaine Chen: Eli Lilly reported more data on its weekly insulin, efsitora alfa. In a Phase 3 trial of type 1 patients, the drug met the primary endpoint of non-inferior A1C reduction compared with a daily insulin called degludec.
But efsitora also led to a higher rate of hypolgycemic events, or cases of dangerously low blood sugar — 14.03 events per patient year of exposure, compared with 11.59 events among patients on degludec. Additionally, 10% of patients on efsirotra experienced severe hypoglycemia, versus 3% of patients on degludec.
While Lilly's weekly insulin has shown in previous trials that it works in type 2 patients without causing a significant increase in hypoglycemic events, the new data raise questions about the safety of its use in type 1 patients.
This is similar to what's been seen with Novo Nordisk's weekly insulin, icodec. The FDA recently rejected Novo's drug, in part due to questions around its use in type 1 patients.
In an interview, Paul Owens, vice president of global brand development for insulins and glucagon at Lilly, wouldn't say what the company's plans and timeline for regulatory submissions are, "but we remain confident in the potential of a once weekly insulin compared to daily insulin."
No comments